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Background. Medical comorbidity has been theorized to contribute to cognitive impairment in heart failure (HF) patients.
Speciﬁcally, type-2 diabetes mellitus (T2DM), a common coexisting condition among HF patients, may be an independent
predictor of cognitive impairment. Nonetheless, the relationships between T2DM and other risk factors for cognitive impairment
among persons with HF are unclear. Methods. Persons with HF (N = 169, 34.3% women, age 68.57 ± 10.28 years) completed
neuropsychological testing within a framework of an ongoing study. History of T2DM, along with other medical characteristics,
was ascertained through a review of participants’ medical charts and self-report. Results. Many participants (34.9%) had a
comorbid T2DM diagnosis. After adjustment for demographic and medical characteristics, HF patients with T2DM evidenced
signiﬁcantly greater impairments across multiple cognitive domains than HF patients without T2DM: λ = .92, F(5,156) = 2.82,
P = .018. Post hoc tests revealed signiﬁcant associations between T2DM and attention (P = .003), executive function (P = .032),
and motor functioning (P = .008). Conclusion. The ﬁndings suggest additive contributions of T2DM and HF to impairments in
attention,executivefunction,andmotorfunction.FutureworkisneededtoelucidatethemechanismsbywhichT2DMexacerbates
cognitive impairment in HF.
1.Introduction
Heart failure (HF) aﬀects nearly six million Americans and
is associated with elevated rates of mortality [1, 2]. HF is
also the most common reason for rehospitalization [3, 4]
and is linked to a number of negative outcomes, including
poor quality of life [5] and reduced ability to perform
instrumental activities of daily living [6, 7].
There is growing evidence that HF is also associated
with poor neurocognitive outcomes. Patients with HF are at
increased risk for Alzheimer’s disease [8, 9], and cognitive
impairment is found in as many as 75% patients with
HF [10]. Cognitive deﬁcits are associated with functional
impairment [11, 12] and increased risk of mortality in this
population[13].Manydemographicandmedicalriskfactors
for cognitive impairment among older adults with HF have
been identiﬁed, including older age [14], depression [15],
hyperglycemia,historyofstroke,elevatedsystolicbloodpres-
sure, metabolic abnormalities (i.e., low serum and anemia)
[14], and high plasma brain natriuretic peptide [16], among
many others.2 Cardiology Research and Practice
Table 1: Demographic and medical characteristics of older heart failure adults with and without type-2 diabetes mellitus (T2DM).
Demographic characteristics Heart failure w/o T2DM Heart failure w/T2DM Total sample
N 110 59 169
Age, mean (SD) 68.85 (11.18) 68.05 (8.42) 68.57 (10.28)
Gender (% women) 33.6 35.6 34.3
Years of education, mean (SD) 13.71 (3.08) 12.87 (2.66) 13.42 (2.96)
Race (% Caucasian) 87.3 74.6 82.8
Medical characteristics
2MST, mean (SD) 64.14 (11.18) 55.12 (25.72) 60.99 (24.06)
BDI-II, mean (SD) 7.08 (6.83) 8.20 (7.33) 7.47 (7.01)
Stroke (%) 10.9 5.1 8.9
Hypertension (%) 64.5 78.0 69.2
MI (%) 54.5 57.6 55.6
Elevated total cholesterol (%) 63.6 72.9 66.9
Note. 2MST: 2-minute step test; BDI II: beck depression inventory-II; MI: myocardial infarction.
Such ﬁndings highlight the important role of medical
comorbidities in the etiology of cognitive impairment in
p e r s o n swi t hH F[ 14]. A condition frequently cooccurring in
HF is type-2 diabetes mellitus (T2DM), with as many as 31%
of patients with HF also having a comorbid T2DM diagnosis
[17]. It is likely that T2DM could be an important contrib-
utor to cognitive dysfunction in HF, as patients with T2DM
are at increased risk for cognitive impairment independent
of HF [18, 19]. One study showed that as many as 18% of
community-residing diabetic older adults exhibit cognitive
impairment and probable dementia [20]. In addition to spe-
ciﬁc impairments on neuropsychological tests of attention
[21], executive function [22], and processing speed [23],
older adults with diabetes also exhibit abnormalities on neu-
roimaging [23]. Moreover, a recent study demonstrated that
when compared to HF patients without T2DM, HF patients
with a coexisting T2DM diagnosis have poorer health,
reduced quality of life, and shorter long-term survival [24].
Despitetheseﬁndings,itremainsunclearwhetherT2DM
and HF have additive eﬀects on cognitive performance.
We examined this possibility in a sample of older adults
with HF after adjusting for other important demographic
variables and medical comorbidities. Secondary analyses
also examined whether T2DM was associated with adverse
psychosocial outcomes (i.e., quality of life and activities of
daily living) among patients with HF. We hypothesized that
HF patients with T2DM would exhibit signiﬁcantly greater
impairments across multiple cognitive domains and have
poorer psychosocial outcomes than those without.
2. Methods
2.1. Participants. A sample of 175 consecutive persons with
HF was selected from an ongoing NIH-funded study on
cognitivefunctioninHF.Afterdata-screeningproceduresthe
samplesizewasreducedto169(seeSection 2.4).Participants
eliminated were not signiﬁcantly diﬀerent from the remain-
ing sample in terms of gender (χ2 (1, N = 175) = 2.65,
P = .104), education (t(173) = −.75, P = .453), depressive
symptomatology (as assessed by the BDI-II) (t(173) = 1.60,
P = .170), or history of diabetes (χ2 (1, N = 175) = .58, P =
.448). However, those eliminated were signiﬁcantly younger
(M = 53.17, SD = 2.32 versus M = 68.57, SD = 10.28) than
the sample analyzed (t(173) = −12.50, P = .000).
Participants were recruited from Summa Health System
in Akron, OH, USA and reﬂect the HF population receiving
treatment at that facility. The inclusion criteria were age of
50–85 years, English as a primary language, and a diagnosis
of New York Heart Association (NYHA) class II or III at the
timeofenrollment.NYHAhistorywasconﬁrmedbymedical
record review. NYHA is one of the most commonly used
systems to classify symptoms of heart disease and is based on
the following scale: (1) mild symptoms with no limitation of
physical activity; (2) mild symptoms with slight limitation of
physical activity, and ordinary physical activity may result in
fatigue, heart palpitations, or shortness of breath; (3) notice-
able limitations of physical activity and less than ordinary
physical activity results in fatigue, heart palpitations, and
shortness of breath; (4) severe limitations of physical activity
with symptoms present at rest and increasing discomfort
with physical activity [25].
Potential participants were excluded for history of signif-
icantneurologicaldisorder(e.g.,dementia),headinjurywith
>10 minutes loss of consciousness, severe psychiatric dis-
order (e.g., schizophrenia and bipolar disorder), substance
use, and renal failure. Participants, averaged 68.57 ± 10.28
yearsofage,were34.3%female,and82.8%Caucasian,11.8%
African American, 4.7% Native American, and 0.6% other.
See Table 1 for demographic and medical information.
2.2. Measures
2.2.1. Neuropsychological Measures. All neuropsychological
tests used in the current study have strong psychometric
properties, including excellent reliability and validity. The
domains and neuropsychological tests administered are as
follows: (1) global cognitive function: Modiﬁed Mini Mental
State Examination (3MS) [26]; (2) attention: Trail MakingCardiology Research and Practice 3
Test A [27] and Digit Symbol Coding [28]; (3) executive
function: Trail Making Test B [29] and Letter Number Se-
quencing (LNS) [30]; (4) memory: The California Verbal
Learning Test-II (CVLT-II) short delay free recall, long delay
free recall and total hits [31]; (5) language: Boston Naming
Test (BNT) [32] and Animal Fluency [33]; and (6) motor:
Grooved Pegboard dominant and nondominant hand [29,
34, 35].
2.2.2. Quality of Life. The Short Form-12 Quality of Life
Measure (SF-12) [36] measures health-related quality of life.
Thetwoprimarycompositescores,PhysicalCompositeScore
(PCS; physical functioning, role-physical, bodily pain, and
general health) and Mental Composite Scale (MCS; vitality,
social functioning, role-emotional, and mental health) were
used in the analyses.
2.2.3. Activities of Daily Living. The Lawton Brody Activities
of Daily Living Scale were used to assess participants’
reported instrumental and basic ADLs. This measure pro-
duces a total ADL score with an overall range between 0 and
28, with higher scores indicative of functional independence
[37].
2.2.4.DepressiveSymptoms. TheBeckDepressionInventory-
II [38] assessed depressive symptomatology in the current
sample. The BDI-II is a commonly used measure with
excellent psychometric properties in persons with medical
conditions[39].BDI-IIscoresrangefrom0to63withhigher
scores indicative of increased symptomatology.
2.2.5. Demographic and Medical History. History of T2DM,
along with other demographic and medical characteristics,
wascollectedthroughareviewofparticipants’medicalcharts
and self-report. Speciﬁcally, a medical record review was
conducted for all participants to corroborate self-report and
to ascertain a physician diagnosis of T2DM. Refer to Table 1.
2.2.6. HF Severity. The 2-minute step test (2MST) is an
assessment of cardiovascular endurance and was used to
serve as an estimate of current heart failure severity [40]. The
2MST requires the patient to march in place for 2 minutes.
The patient is asked to bring each knee up to a marked target
set on the wall at the individual’s own midpoint between
the kneecap and crest of the iliac. The number of times that
the right knee met the marked target was counted. Higher
step count within the 2 minutes was reﬂective of greater
cardiovascular ﬁtness.
The 2MST has been suggested to be an alternative
to the 6-minute walk test, which has been linked with
functional work capacity, maximal oxygen uptake, and poor
prognosis in patients with HF [41, 42]. Recent work has also
shown decreased performance on the 2MST to be associated
with worse cognitive function in patients with HF [43]. In
addition to these ﬁndings, the 2MST oﬀers many practical
advantagesasitisbrief,canbeconductedwithintheconﬁnes
of an examination room, and it is practical for patients
with orthopedic devices or poor balance (i.e., patients are
permitted to use the wall or a chair for support while
performing the 2MST) [40, 44].
2.3. Procedures. The local Institutional Review Board (IRB)
approved the study procedures, and all participants provided
written informed consent prior to study enrollment. Partic-
ipants completed demographic, medical, and psychosocial
self-report measures. A brief neuropsychological test battery
was then administered to all heart failure participants to
assess attention, executive function, memory, language, and
motor functioning. Individuals then completed the 2MST
under supervision.
2.4. Statistical Analyses. To facilitate clinical interpretation
and to avoid undue inﬂuence of discrepancy in scales, all
raw scores of the neuropsychological measures assessing cog-
nitive function were transformed to t scores (a distribution
with a mean of 50, and a standard deviation of 10) using
normative data correcting for age. Composite scores for
attention,executive,memory,language,andmotorfunctions
were means of the t scores within each cognitive domain.
Consistentwithconventioninmanyclinicalsettings,impair-
ment in these domains for the current study was deﬁned as
a t score of 1.5 standard deviations below the mean (t<35).
Screening of the data revealed outliers disrupting univariate
normality on executive function, and motor domains, thus
these cases were eliminated from analyses (n = 6).
To examine the additive eﬀe c to fT 2 D Mo nc o g n i t i v e
impairment, a multivariate analysis of covariance
(MANCOVA) was performed using attention, executive,
memory, language, and motor functions as the dependent
variables. Current medical history of T2DM served as the
independent variable for each analysis. Demographic and
medical variables including gender, education, depressive
symptomatology (as assessed by the BDI-II), heart failure
severity (as estimated by the 2MST), and history of stroke,
hypertension,myocardialinfarction,andelevatedcholesterol
were all entered as covariates. Age was not included as a
covariate because the neuropsychological tests comprising
the cognitive domains were corrected for age using
normative data. A series of independent samples t-tests were
then conducted to examine diﬀerences between older HF
adults with and without T2DM on psychosocial measures
assessing quality of life and activities of daily living.
3. Results
3.1. Demographic and Medical Diﬀerences between HF Pa-
tients with and without T2DM. Independent samples t-
test and χ2 statistics were computed to identify diﬀerences
between HF patients with and without T2DM on important
demographic and medical variables. No signiﬁcant between-
group diﬀerences were found for age (t(167) = −.483, P =
.629), gender (χ2 (1, N = 169) = .07, P = .798), education
(t(167) = −1.76, P = .080), race (χ2 (3, N = 169) =
5.967, P = .113), or depressive symptomatology (t(167) =
.99, P = .323). There were also no signiﬁcant group
diﬀerences on any of the medical comorbidities, including4 Cardiology Research and Practice
Table 2: Cognitive impairment in older heart failure adults with and without type 2 diabetes mellitus.
Cognitive
domain
Total sample T
score, mean (SD)
(N = 169)
% <35 T score
Total sample
(N = 169)
%H Fw / T 2 D MT
score <35
(N = 110)
%H Fw / oT 2 D M
Ts c o r e<35
(N = 59)
χ2 (p)
Attention 48.40 (9.62) 7.7 11.9 5.5 2.22 (.14)
Executive
Function 47.36 (11.32) 11.2 15.3 9.1 1.46 (.23)
Memory 45.89 (9.56) 10.7 10.2 10.9 .02 (.88)
Language 51.66 (11.15) 8.3 11.9 6.4 1.53 (.22)
Motor 36.91 (14.18) 34.3 49.2 26.4 8.85 (<.01)
Abbreviations: HF w/T2DM: heart failure with type-2 diabetes mellitus; HF w/o T2DM: heart failure without type-2 diabetes mellitus.
history of hypertension (χ2 (1, N = 169) = 3.25, P = .072),
myocardial infarction (χ2 (1, N = 169) = .15, P = .701), or
total elevated cholesterol (χ2 (1, N = 169) = 1.48, P = .224).
However, when compared to HF patients without T2DM,
HF patients with T2DM performed signiﬁcantly worse on
the 2MST (i.e., evidenced poorer cardiovascular ﬁtness)
(t(167) = −2.35, P = .020). Additionally, although there
were no statistically signiﬁcant between group diﬀerences on
history of stroke at the P<. 05 level (χ2 (1, N = 169) = 1.61,
P = .204), HF patients without T2DM were nearly twice as
likely to have a positive history of stroke than HF patients
with T2DM. See Table 1 for details. However, it is important
to note that all individuals were carefully screened for the
presence of any neurological disorder likely to inﬂuence
cognitive test performance. As such, patients identiﬁed with
history of “stroke” were more accurately diagnosed with
terms such as “cerebrovascular disease” and “white matter
disease” rather than the stereotypic features of a cortical
stroke (i.e., loss of language, hemiparesis, etc.).
3.2. Cognitive Impairment. T2DM was common in the
current sample of HF patients, with 34.9% having a positive
medical history of T2DM. Cognitive impairment was also
common, as the sample mean 3MS score was 92.79 ± 5.36.
Speciﬁcally, 24.3% of the participants had a 3MS score below
90, and 39.0% had a 3MS score between 90 and 95 and
36.7% of the sample had a 3MS score between 95 and 100.
HF patients with T2DM performed worse on the 3MS than
HF patients without T2DM (t(167) = −2.02, P = .045). HF
patientswithT2DMhadanaverage3MSscoreof91.66±5.37
(N = 59), whereas HF patients without T2DM had an
average 3MS of 93.39 ±5.28 (N = 110).
ByaT-scorecutoﬀof35,manyHFpatientscouldbeclas-
siﬁed as impaired on tests of attention, executive function,
memory, language, and motor functioning. Impairment in
motor functioning (χ2 (1, N = 169) = 8.85, P = .003)
was more common in HF patients with T2DM than those
without (see Table 2).
3.3. T2DM and Cognitive Function in Older Adults with HF.
After adjusting for gender, education, BDI-II, 2MST, and
history of stroke, hypertension, myocardial infarction, and
elevated cholesterol MANCOVA revealed a signiﬁcant main
eﬀect of T2DM diagnosis across multiple cognitive domains:
Λ = .92, F(5, 156) = 2.82, P = .018. Post hoc tests showed
HF patients with T2DM had poorer performance on tests of
attention (F(8, 160) = 9.29, P = .003), executive function
(F(8, 160) = 4.69, P = .032), and motor functioning (F(8,
160) =7.30,P = .008).Nosuchpatternemergedformemory
(P = .635) or language (P = .599). See Table 3 for a full
summary of group diﬀerences in cognitive performance.
3.4. T2DM and Performance on Speciﬁc Neuropsychological
Tests. Follow-up MANCOVA analyses adjusting for gender,
education, BDI-II, 2MST, and history of stroke, hyperten-
sion, myocardial infarction, and elevated cholesterol were
performed to clarify the relationship between T2DM and
performanceonneuropsychological testsassessing attention,
executive function, and motor functioning. Bonferroni-
correctedposttestssigniﬁcancelevel,setatP = .017,revealed
that HF patients with T2DM performed signiﬁcantly worse
than those without T2DM on Digit Symbol Coding (F(9,
159) = 11.29, P = .001), Trail Making Test B (F(9, 159) =
6.63, P = .011), and Grooved Pegboard with dominant (F(9,
159) = 6.34, P = .013), and nondominant (F(9, 159) = 6.68,
P = .011) hands.
3.5. T2DM and Psychosocial Outcomes in Older Adults with
HF. A series of independent samples t-tests revealed group
diﬀerences in quality of life and ADL function as assessed
by the SF-12 PCS (t(167) = −2.59, P = .011) and total
ADL (t(99.96) = −2.01, P = .048) scores. HF patients
with T2DM reported signiﬁcantly poorer physical quality of
life and reduced ability to perform ADLs than HF patients
without T2DM. No such pattern emerged on the SF-12 MCS
(t(167) = −.52, P = .605). See Table 4 for details.
4. Discussion
Consistent with past work, cognitive impairment was com-
mon in current sample of older adults with HF. Medical
comorbiditiesamongpatientswithHFhavebeenlinkedwith
increased risk of cognitive impairment in this population,
includinghypertensionandhyperglycemia[14,45].Thecur-
rentstudyextendstheseﬁndingsbyshowingthatolderadults
with HF and T2DM have greater impairments in cognitive
function than those with HF alone. Such ﬁndings suggestCardiology Research and Practice 5
Table 3: T-score means and standard deviations of cognitive test performance for heart failure patients with and without type-2 diabetes
mellitus.
Cognitive domains
Attention Executive
function Memory Language Motor
HF w/T2DM
(N = 110) 44.57 (9.64) 43.81 (13.24) 45.31 (9.15) 50.03 (13.22) 31.87 (14.89)
HF w/o
T2DM
(N = 59)
50.45 (8.99) 49.26 (9.67) 46.20 (9.80) 52.53 (9.82) 39.61 (13.07)
F 9.29∗∗ 4.69∗ .23 .28 7.30∗∗
Performance on neuropsychological tests of attention, executive function, and motor
TMTA Digit TMTB LNS PegsD PegsND
HF w/T2DM
(N = 110) 45.60 (13.45) 43.54 (8.23) 38.17 (20.31) 49.45 (8.39) 29.51 (18.54) 34.23 (12.51)
HF w/o
T2DM
(N = 59)
51.17 (10.70) 49.72 (9.19) 47.16 (13.49) 51.38 (9.40) 38.56 (15.76) 40.67 (11.83)
F 4.53∗ 11.29Ψ 6.63Ψ .28 6.34Ψ 6.68Ψ
Note. ∗= P<. 05; ∗∗= P<. 01; Ψ= P<. 017.
Abbreviations: HF w/T2DM: heart failure with type-2 diabetes mellitus; HF w/o T2DM: heat failure without type-2 diabetes mellitus; TMTA: trail making
test A; digit: digit symbol coding; TMTBL: trail making test B; LNS: letter number sequencing; PegsD: grooved pegboard dominant hand; PegND: grooved
pegboard nondominant hand.
Table 4:Meansandstandarddeviationsofpsychosocialoutcomesamongolderheartfailureadultswithandwithouttype2diabetesmellitus.
SF-12 PCS SF-12 MCS Total ADL
HF w/T2DM 42.10 (8.78) 51.72 (9.64) 24.54 (3.60)
(N = 110)
HF w/o T2DM 45.49 (7.74) 52.54 (9.97) 25.64 (2.93)
(N = 59)
t (df) −2.59 (167)∗ −.52 (167) −2.13 (99.96)∗
Note. ∗=P<. 05.
Abbreviations: HF w/T2DM: heart failure with type-2 diabetes mellitus; HF w/o T2DM: heart failure without type-2 Diabetes mellitus; SF-12 PCS: SF-12
physical composite score; SF-12 MCS: SF-12 mental composite scale; Total ADL: total score on activities of daily living.
that T2DM may be an additional risk factor for cognitive
impairment in this population.
The current study suggests that HF patients with T2DM
have additive impairments in cognitive functioning, includ-
ing attention, executive function and motor functioning.
Patients with diagnosis of either HF or T2DM exhibit high
rates of cognitive impairment in these domains [10, 17].
Moreover, elevated fasting glucose in clinically normal
adults is associated with reduced performance in executive
functions [46]. Past work on the etiology of cognitive
impairment in persons with HF has identiﬁed reduced
cerebral perfusion as a result of left ventricular dysfunction
[47]andaseriesofcomorbidconditions(e.g.,hyperglycemia
and stroke history) [14] as important factors. The current
ﬁndings suggest that T2DM is also an important contributor
to cognitive impairment in HF. Such ﬁndings are perhaps
not surprising given the growing evidence for adverse neu-
rocognitive outcomes in persons with T2DM. For example,
poor glycemic control and resulting cerebral microvascular
and macrovascular damage (including reduced endothelial
functioning) among patients with T2DM have been shown
to be associated with cognitive impairment [20, 21, 48–
50]. Interestingly, HF is associated with increased risk of
Alzheimer’s disease (AD) [8, 9], and the high insulin levels
often observed in patients with T2DM have also been
correlated with greater levels of amyloid-beta protein—an
early indicator of AD pathogenesis [51–53]. Future work is
needed to clarify the mechanisms by which HF and T2DM
may interact.
Follow-up analyses showed that HF patients with T2DM
demonstrated greater impairments on a task of psychomo-
tor speed and speeded tasks of attention and executive
function. Indeed, past work has shown T2DM patients
(independent of HF) to be associated with reduced per-
formance on speeded neuropsychological measures and
poorer psychomotor eﬃciency [54, 55]. Consistent with
these ﬁndings, patients with T2DM often exhibit a cognitive
pattern consisting of decreased mental speed and ﬂexibility
[56]. Increased cognitive slowing is an early indicator of
cognitive impairment in dementia [57]; thus, future studies
should examine whether HF patients with T2DM are at
elevated risk for dementia.6 Cardiology Research and Practice
The current study found no additive eﬀect of T2DM on
memory in older adults with HF. While HF has been linked
to impairments in memory, past work suggests that these
deﬁcits may be a result of an interaction between older age
andlowejectionfraction[58].Similarly,pastworkhaslinked
T2DM to memory impairment, with poor test performance
being closely associated with longer T2DM duration and
diseaseprogression[53,59].Theexactreasonfortheabsence
of an additive eﬀect of T2DM on memory in the current
sample is unclear. One possible explanation is the absence
of direct measures of glycemic control and insulin resistance
in the current study. Recent studies suggest that many HF
patients exhibit impaired insulin resistance [60] and that this
process may occur independent of body composition [61].
As a result, it is possible that participants in the HF-only
group of the current study actually exhibit some degree of
insulin resistance, and these processes have recently been
associated with poorer cognitive function [62]. Future work
is needed to clarify this and other possible explanations.
In addition to poorer cognitive function, the current
ﬁndings also indicate that HF patients with T2DM are
at greater risk for reduced functional abilities and poorer
quality of life. Such ﬁndings are consistent with past work
demonstrating HF patients with T2DM to have reduced
health-related quality of life [24]. Cognitive impairment may
have a profound eﬀect in the treatment management of
T2DM in HF patients (i.e., poorer adherence to medica-
tion; dietary and physical activity recommendations). For
instance, recent work found that cognitive impairment is
associated with reduced functional independence in older
adults with HF [6], and other work shows greater cognitive
impairment among older adults with T2DM is related with
poorer disease care management and adherence [63]. Addi-
tionally, the current study’s ﬁndings that HF patients with
T2DM reported that a signiﬁcantly worse physical quality of
life, as opposed to mental quality of life, than HF patients
without T2DM has signiﬁcant implications. For example,
previous animal studies have shown physical activity to
improve insulin resistance and attenuate neuroautonomic
dysregulationamongratswithcardiovasculardiseaseandHF
[64, 65]. Future work should investigate whether physical
activity in humans also produces similar metabolic changes
and the possibility that such changes would reduce the
adverse eﬀects of T2DM on cognitive function in HF
patients. Similarly, future studies should also explore the
possibility that additive deﬁcits in cognitive function due
to multiple comorbidities may be an important cause for
adverse psychosocial outcomes in persons with both HF and
other common medical conditions in older adults.
Several limitations of the current study merit brief
review. First, the present study consisted of cross-sectional
data and prospective studies are needed to examine the
trajectory of cognitive decline to clarify the relationship
of T2DM and cognitive impairment in HF. Additionally,
future studies are needed to identify the mechanisms of the
adverse eﬀects of T2DM on cognitive function among older
adults with HF. Past work suggests cognitive impairment in
patients with T2DM to be a result of the negative eﬀects of
hyperglycemia and glycation end products on the vascular
system, including reduced cerebral blood ﬂow and poorer
endothelial functioning [21]. In addition, hyperinsulinemia
in T2DM patients has also been linked with cerebral amyloid
and tau metabolism [66]. Future studies should examine
whether HF patients with T2DM are at greater risk of
cognitive impairment through these and other mechanisms.
Finally,thecurrentstudyexaminedHFasabroaddisease
entity, and speciﬁc type of HF (i.e., diastolic or systolic) was
not examined. While previous research has shown systolic
and diastolic HF to both be associated with worse cognitive
function [67], the nature by which these HF etiologies
interact with T2DM to produce cognitive dysfunction may
be distinct. Future work should examine the additive eﬀects
of T2DM across HF types. Similarly, the current study
examinedHFseverityusingthe2MST,whichhasbeenlinked
with cognitive function in HF persons [43] and also has
several practical advantages over commonly used walk tests.
However, examining the interaction between T2DM and HF
severity using measures such as VO2 max, cardiac output,
and/or ejection fraction would provide clearer insight into
the eﬀects of T2DM on cardiac functioning. Additionally,
future studies should also investigate the contribution of
insulin resistance to cognitive function within HF patients
using more sophisticated measures (e.g., HbA1C, oral glu-
cose tolerance testing) and to also investigate disease dura-
tion. Lastly, the relatively small sample size in the current
study did not permit analyses to control for key variables
such as medication status and larger samples of HF patients
with T2DM that are needed to further elucidate the indepen-
dent additive eﬀects of T2DM on cognitive function in HF.
In brief summary, the current study demonstrates that
HF patients with T2DM have greater cognitive impairments
than HF patients without T2DM. Future work is needed
to elucidate the mechanisms by which T2DM exacerbates
cognitive impairment in older adults with HF.
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